Development of a Treatment Prognosis Calculator for the Prevention of Suicide

Sponsor
Ohio State University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06094218
Collaborator
United States Department of Defense (U.S. Fed)
1,200
2
34.5

Study Details

Study Description

Brief Summary

The goal of this interventional study is to develop and test a treatment prognosis calculator to identify which service members with suicidal ideation or behavior are likely to respond well to the current standard of care treatment and which should instead receive Brief Cognitive Behavioral Therapy (BCBT) as a first-line treatment.

The main aims of the study are:
  • Aim 1: To develop a novel treatment prognostic calculator to predict response to treatment as usual (TAU) and identify treatment-seeking military personnel who are unlikely to respond adequately to TAU for the reduction of suicidal ideation.

  • Aim 2: To evaluate the performance of the treatment prognosis calculator in a new sample of treatment-seeking military personnel and determine whether BCBT is more effective than TAU for those patients who are predicted not to respond adequately to TAU.

Participants will receive mental health treatment as it is typically administered by their mental healthcare treatment team. Members of their mental healthcare treatment team may receive intensive training in BCBT. After their provider has received this training, they may use this treatment as part of standard of care treatment. The timing of this training will be determined randomly. Participants will complete self-report assessments at the beginning of the study (baseline) as well as 3, 6, 9 and 12 months after their participant begins. These assessments will include questions about feelings, thoughts, moods, impulses, substance use, and behavior.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Brief Cognitive Behavioral Therapy (BCBT)
  • Behavioral: Treatment as usual (TAU)
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
1200 participants
Allocation:
Randomized
Intervention Model:
Sequential Assignment
Intervention Model Description:
This study is a two phase, stepped-wedge design. In Phase I, all participants receive TAU. In Phase II, sites are randomized to receive training in BCBT. Prior to the training, participants receive TAU. Following the training, participants may receive BCBT.This study is a two phase, stepped-wedge design. In Phase I, all participants receive TAU. In Phase II, sites are randomized to receive training in BCBT. Prior to the training, participants receive TAU. Following the training, participants may receive BCBT.
Masking:
Single (Participant)
Primary Purpose:
Prevention
Official Title:
Development of a Treatment Prognosis Calculator for the Prevention of Suicide
Anticipated Study Start Date :
Oct 17, 2023
Anticipated Primary Completion Date :
Aug 31, 2025
Anticipated Study Completion Date :
Aug 31, 2026

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Treatment as Usual (TAU)

TAU may include (1) routine suicide risk screening and assessment; (2) safety planning with means restriction; and (3) the Collaborative Assessment and Management of Suicidality (CAMS), an evidence-based approach to managing and treating suicidal patients.

Behavioral: Treatment as usual (TAU)
Behavioral health treatment as it is typically provided at the treatment site.

Experimental: Brief Cognitive Behavioral Therapy (BCBT)

BCBT consists of 12 outpatient individual psychotherapy sessions scheduled weekly or biweekly. The first session is 90 minutes and subsequent sessions are 60 minutes. BCBT is divided into three phases. In phase 1 (5 sessions), the therapist conducts a detailed assessment of the patient's most recent suicidal episode or suicide attempt, identifies patient-specific factors that contribute to and maintain suicidal behaviors, provides a cognitive-behavioral conceptualization, collaboratively develops a crisis response plan, and teaches basic emotion regulation skills. In phase 2 (5 sessions), the therapist teaches cognitive restructuring skills to build cognitive flexibility. In phase 3 (2 sessions), a relapse prevention task is conducted, and participants must demonstrate the ability to successfully complete this task in order to terminate the treatment. Additional sessions are conducted until participants demonstrate the ability to successfully complete this task.

Behavioral: Brief Cognitive Behavioral Therapy (BCBT)
BCBT was developed to provide patients with the skills they need to better manage the cognitive, emotional, physiological, and behavioral components of acute suicidal crises.

Outcome Measures

Primary Outcome Measures

  1. Suicidal Ideation [6 Months]

    Assess severity of suicidal ideation at 6 months with the Scale for Suicide Ideation (SSI)

Secondary Outcome Measures

  1. Suicide Attempts [12 Months]

    Suicide attempts will be assessed with the Self-Injurious Thoughts and Behaviors Interview-Revised (SITBI-R)

  2. Depression [12 Months]

    Depression will be assessed with the PROMIS-Depression Computer Adaptive Test (CAT)

  3. Hopelessness [12 Months]

    Hopelessness will be assessed with the abbreviated Beck Hopelessness Scale (BHS)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. female and male active duty service members;

  2. => 18 years old;

  3. engaged in mental health treatment at one of the sites at study enrollment;

  4. score >0 on the Columbia Suicide Severity Rating Scale (CSSRS) Screener-Recent, indicating suicidal ideation within the last month;

  5. able to understand and speak English;

  6. able to provide consent.

Exclusion Criteria:

(1) participants with a psychiatric or medical condition that prevents them from providing informed consent or from participating in the treatments (e.g., psychosis, mania, acute intoxication).

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Ohio State University
  • United States Department of Defense

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Jay Fournier, Associate Professor, Department of Psychiatry & Behavioral Health, Ohio State University
ClinicalTrials.gov Identifier:
NCT06094218
Other Study ID Numbers:
  • 2022H0245
First Posted:
Oct 23, 2023
Last Update Posted:
Oct 23, 2023
Last Verified:
Oct 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 23, 2023